GlassScriptPhysician profile
Srinivasa R Ayinala
NPI 1285624148
$8,457.63
in general payments reported to CMS, 2019-2025
39 companies · $2,106 in 2025
The $2,106 reported for 2025 was more than what 80% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $748 · 2020: $444 · 2021: $964 · 2022: $1,585 · 2023: $925 · 2024: $1,687 · 2025: $2,106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,700 · Education: $17.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,700.34 |
| Education | $17.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,003.50 | 2019-2025 | Linzess, Viberzi, Creon |
| Takeda Pharmaceuticals U.S.A., INC. | $829.02 | 2019-2025 | Entyvio |
| Redhill Biopharma INC. | $478.14 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $441.19 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Regeneron Healthcare Solutions, INC. | $385.95 | 2022-2025 | Dupixent |
| Genzyme Corporation | $329.37 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $313.74 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $276.55 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Biotech, INC. | $274.31 | 2019-2025 | Stelara, Tremfya |
| Pfizer INC. | $266.01 | 2021-2025 | |
| Olympus America INC. | $254.29 | 2022 | |
| Intercept Pharmaceuticals, INC. | $252.77 | 2022-2025 | Ocaliva |
| Ipsen Biopharmaceuticals, INC | $238.03 | 2023-2025 | Iqirvo, Bylvay |
| Gilead Sciences, INC. | $219.68 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $211.53 | 2019-2022 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $204.13 | 2024-2025 | Omvoh, Zepbound |
| Boston Scientific Corporation | $164.79 | 2021-2025 | Exalt Model D, Watchman Flx |
| Medtronic, INC. | $163.26 | 2025 | Gi Genius |
| Celltrion USA INC. | $160.29 | 2023-2025 | Vegzelma, Yuflyma |
| Organon LLC | $143.42 | 2021-2025 | Hadlima, Renflexis |
| Ironwood Pharmaceuticals, INC | $140.22 | 2020-2021 | |
| Ucb, INC. | $96.73 | 2019 | |
| Nestle Healthcare Nutrition INC. | $69.10 | 2021-2023 | |
| Celgene Corporation | $64.99 | 2022-2024 | Zeposia |
| Mallinckrodt Hospital Products INC. | $62.56 | 2025 | Terlivaz |
| Vivus LLC | $53.69 | 2021-2025 | Pancreaze, Qsymia |
| Daiichi Sankyo INC. | $42.34 | 2019-2021 | |
| Ardelyx, INC. | $41.28 | 2025 | Ibsrela |
| Intra-Sana Laboratories | $39.57 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $38.90 | 2024-2025 | Zenpep |
| Qol Medical, LLC | $36.04 | 2025 | Sucraid |
| Evoke Pharma, INC. | $31.04 | 2020-2022 | |
| Amgen INC. | $25.91 | 2025 | Uplizna |
| Allergan, INC. | $23.13 | 2019 | |
| Shire North American Group INC | $20.43 | 2019 | |
| Stryker Corporation | $18.40 | 2024 | Surgicount |
| Mylan Institutional INC. | $17.77 | 2023 | |
| Ferring Pharmaceuticals INC. | $13.43 | 2019 | |
| Braintree Laboratories, INC. | $12.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Srinivasa Ayinala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.